Imaging in early phase childhood cancer trials

Pediatric Radiology

Volumn 39, Issue SUPPL. 1, 2009, Pages

  Adamson, Peter C ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Clinical trials; Pediatric cancer; Pharmacodynamics; Pharmocokinetics

Indexed keywords

BEVACIZUMAB; DASATINIB; ERLOTINIB; FLUORINE 18; GEFITINIB; IMATINIB; SORAFENIB; SUNITINIB; VASCULOTROPIN; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HUMAN; KIDNEY CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT IDENTIFICATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CHILD; DRUG EFFECT; METABOLISM; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SIGNAL TRANSDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 63249104713     PISSN: 03010449     EISSN: 14321998     Source Type: Journal    
DOI: 10.1007/s00247-008-1016-5     Document Type: Conference Paper

References (32)

1. A Jemal R Siegel E Ward 2006 Cancer statistics, 2006 CA Cancer J Clin 56 106 130
2. Adamson PC, Weiner SL, Simone JV et al (2005) Making better drugs for children with cancer. Committee on Shortening the Time Line for New Cancer Treatments, National Cancer Policy Board. Institute of Medicine, Washington, DC
3. Ries L, Melbert D, Krapcho M et al (2008) SEER Cancer Statistics Review, 1975-2005. National Cancer Institute, Bethesda, MD, based on November 2007 SEER data submission. Available via http://seer.cancer.gov/csr/1975-2005/index.html
4. S Bhatia AT Meadows 2006 Long-term follow-up of childhood cancer survivors: future directions for clinical care and research Pediatr Blood Cancer 46 143 148 (Pubitemid 43076063)
5. KC Oeffinger AC Mertens CA Sklar 2006 Chronic health conditions in adult survivors of childhood cancer N Engl J Med 355 1572 1582 (Pubitemid 44547808)
6. R Skinner WH Wallace GA Levitt 2006 Long-term follow-up of people who have survived cancer during childhood Lancet Oncol 7 489 498 (Pubitemid 44207842)
7. BJ Druker S Tamura E Buchdunger 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat Med 2 561 566 (Pubitemid 26151518)
8. BJ Druker M Talpaz DJ Resta 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 (Pubitemid 32267972)
9. S Madhusudan TS Ganesan 2004 Tyrosine kinase inhibitors in cancer therapy Clin Biochem 37 618 635 (Pubitemid 38845024)
10. G Vlahovic J Crawford 2003 Activation of tyrosine kinases in cancer Oncologist 8 531 538 (Pubitemid 37467368)
11. C Gridelli MA Bareschino C Schettino 2007 Erlotinib in non-small cell lung cancer treatment: current status and future development Oncologist 12 840 849 (Pubitemid 47328227)
12. R Nanda 2007 Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions Rev Recent Clin Trials 2 111 116 (Pubitemid 46773878)
13. E Buchdunger CL Cioffi N Law 2000 Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 139 145
14. HM Linden SA Stekhova JM Link 2006 Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer J Clin Oncol 24 2793 2799 (Pubitemid 46630578)
15. KT Flaherty MA Rosen DF Heitjan 2008 Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma Cancer Biol Ther 7 496 501
16. BJ Druker 2002 Perspectives on the development of a molecularly targeted agent Cancer Cell 1 31 36 (Pubitemid 41039173)
17. ML Lux BP Rubin TL Biase 2000 KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors Am J Pathol 156 791 795 (Pubitemid 30626936)
18. GD Demetri M von Mehren CD Blanke 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480
19. CH Holdsworth RD Badawi JB Manola 2007 CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor Am J Roentgenol 189 W324 W330 (Pubitemid 350174810)
20. MA Champagne R Capdeville M Krailo 2004 Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study Blood 104 2655 2660 (Pubitemid 39434944)
21. F Millot J Guilhot B Nelken 2006 Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation Leukemia 20 187 192 (Pubitemid 43148651)
22. R Aplenc LC Strauss S Shusterman 2008 Pediatric phase I trial and pharmacokinetic (PK) study of dasatinib: a report from the Children's Oncology Group Phase I Consortium ASCO Meeting Abstracts 26 3591
23. RJ Gilbertson 2004 Medulloblastoma: signalling a change in treatment Lancet Oncol 5 209 218 (Pubitemid 38391216)
24. RJ Gilbertson L Bentley R Hernan 2002 ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease Clin Cancer Res 8 3054 3064 (Pubitemid 35155014)
25. RJ Gilbertson DA Hill R Hernan 2003 ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma Clin Cancer Res 9 3620 3624 (Pubitemid 37169226)
26. NC Daw WL Furman CF Stewart 2005 Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study J Clin Oncol 23 6172 6180 (Pubitemid 46300236)
27. BB Freeman 3rd NC Daw JR Geyer 2006 Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients Cancer Invest 24 310 317
28. RI Jakacki J Tersak S Blaney 2006 A pediatric phase I trial and pharmacokinetic (PK) study of erlotinib (ERL) followed by the combination of ERL with temozolomide (TMZ): a Children's Oncology Group study Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings Part I 24 A9015
29. JL Bender PC Adamson JM Reid 2008 Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study J Clin Oncol 26 399 405
30. SG DuBois S Shusterman AM Ingle 2008 A pediatric phase I trial and pharmacokinetic (PK) study of sunitinib: a Children's Oncology Group phase I consortium study ASCO Meeting Abstracts 26 3561
31. Shankar LK (2008) Molecular imaging in evaluating treatment response. SNM Annual Meeting, New Orleans, LA
32. PhRMA 2008 report: Medicines in Development for Cancer. PhRMA, Washington